Shionogi (TYO:4507) said Taiwan's Food and Drug Administration accepted the new drug application for ensitrelvir fumaric acid submitted by its Taiwanese subsidiary.

A contract for purchasing ensitrelvir for government stockpiling was also finalized with the Taiwan Centers for Disease Control, according to a Wednesday bourse filing.

Ensitrelvir is an oral antiviral that inhibits SARS-CoV-2 replication, and while it has full approval in Japan and special access in Singapore, it remains investigational elsewhere.

Price (JPY): $2263.00, Change: $+31, Percent Change: +1.39%